Orthopedic Surgery Doctors in New Haven, CT Accepting Medicare

46 Orthopedic Surgery doctors found. Showing 41 - 46

Dr. Lisa L. Lattanza, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 47 College St Fl 2, New Haven, CT 06510 Phone: 203-785-5461    Fax: 415-885-3862

Dr. David Benjamin Frumberg, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 800 Howard Ave, New Haven, CT 06519 Phone: 203-785-2579

Lauren K Szolomayer, M.D. Orthopaedic Surgery - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 York St # T-209, Yale New Haven Hospital, New Haven, CT 06510 Phone: 203-785-6900    Fax: 203-737-4687

Daniel R Cooperman, MD Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 1 Long Wharf Dr, New Haven, CT 06511 Phone: 203-785-4081

Jonathan Newman Grauer, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 800 Howard Ave, Yale Physicians Building, New Haven, CT 06519 Phone: 203-785-2140    Fax: 203-785-6414

Dr. Adrienne Ruth Socci, MD Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 800 Howard Ave, Yale Physicians Building, Fl 1, New Haven, CT 06519 Phone: 203-785-2579    Fax: 203-785-7132

News Archive

Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda

Affymax, Inc. today announced that it has received $30 million in development milestone payments from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™/peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.

ImmunoGen decides to stop IMGN901 Phase II SCLC study

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, announced today the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial's independent Data Monitoring Committee.

Topline results from Alkermes' ALKS 37 phase 2b study on opioid-induced constipation

Alkermes plc today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multicenter, randomized, double-blind, placebo-controlled, repeat-dose study was designed to assess the safety, tolerability, pharmacokinetic profile and efficacy of ALKS 37 in approximately 150 patients.

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

Read more Medical News

› Verified 7 days ago

• 1
• 2
• 3(current)